Clinical trials
Membranous Nephropathy clinical trials
Below are recruiting membranous nephropathy clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
Birmingham, AlabamaAges 18–75 - NCT04095156Recruiting
Study of immune B cells in membranous nephropathy
This study looks at immune “B cells” in people with membranous nephropathy (a kidney disease). It includes people who have received or are being considered for B-cell–depleting treatment, aiming to better understand what drives the disease and how it may respond.
Ranica, BGAges 18 years+ - NCT04326218Recruiting
Understanding Immune Causes of Kidney Membrane Disease
This study examines blood and kidney tissue samples from people with membranous nephropathy—a condition where the kidney's filtering membrane is damaged by the immune system. Researchers are trying to understand which immune markers predict how the disease will progress and respond to treatment.
Nice, Alpes MaritimeAges 18 years+ - NCT05839314RecruitingPhase 4
Huaier granules for idiopathic membranous nephropathy with PLA2R
This trial studies whether Huaier granules can improve kidney disease activity in people with “idiopathic membranous nephropathy” who test positive for PLA2R antibodies and are still not in remission. Participants will also have been on standard blood-pressure/kidney-protecting treatment (called RASI) for at least 4 weeks.
Beijing, Beijing MunicipalityAges 18–75 - NCT06242327Recruiting
Study of outcomes in primary membranous nephropathy
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
Bergamo, BGAges 18 years+ - NCT06982729RecruitingPhase 1
Testing YK012 for primary membranous nephropathy
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
Beijing, Beijing MunicipalityAges 18–80 - NCT06573411RecruitingPhase 4
Finerenone for primary membranous nephropathy
This trial tests if finerenone, a medicine that may protect the kidneys, can help people with primary membranous nephropathy (a kidney disease that causes protein in urine). It is for adults who are already taking a standard blood pressure medicine but still have protein in their urine.
Guangzhou, GuangdongAges 18 years+ - NCT05514015RecruitingPhase 4
Rituximab with steroids or rituximab alone for membranous kidney disease
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Guangzhou, GuangdongAges 18–75 - NCT07096843RecruitingPhase 2
Study of Budoprutug for Primary Membranous Nephropathy
This trial tests an investigational drug called budoprutug for people with primary membranous nephropathy, a kidney condition. The goal is to see if the drug can reduce protein in the urine and help protect kidney function.
Denver, ColoradoAges 18–75 - NCT06470191RecruitingPhase 2/Phase 3
B007 for primary membranous nephropathy
This trial tests a new drug called B007 for people with primary membranous nephropathy, a kidney condition. It aims to see if B007 can help reduce protein in the urine and protect kidney function.
BeijingAges 18–80 - NCT05668403RecruitingPhase 1
Subcutaneous anti-CD20 antibody for primary membranous nephropathy
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
Zhengzhou, He'nanAges 18–75 - NCT07289763RecruitingPhase 2
Study of SHR-2173 for primary membranous nephropathy
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Nanjing, JiangsuAges 18–75 - NCT05696613RecruitingPhase 3
Study of a hormone gel for high-risk membranous nephropathy
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT06341205RecruitingPhase 3
Personalized rituximab for membranous nephropathy using AI
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
BesançonAges 18 years+ - NCT07266181RecruitingPhase 1
CAR-T cell therapy for tough-to-treat membranous nephropathy
This trial tests whether specially engineered immune cells (CAR-T cells) can help people with a kidney condition called primary membranous nephropathy that has not improved with standard treatments. The goal is to see if this therapy can reduce protein in the urine and protect kidney function.
Xi'an, ChinaAges 18 years+ - NCT07404436RecruitingPhase 4
Blood thinner to prevent clots in kidney disease
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
Beijing, Beijing MunicipalityAges 18–80 - NCT06962800RecruitingPhase 3
Study of felzartamab for adults with primary membranous nephropathy
This study tests whether felzartamab, given as an infusion, can help treat primary membranous nephropathy (a kidney disease causing protein in the urine and swelling). It may reduce protein loss and improve kidney function compared to standard care alone.
Huntsville, AlabamaAges 18–80 - NCT07157787RecruitingPhase 2
Testing a new drug for primary membranous nephropathy
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
Loma Linda, CaliforniaAges 18–75 - NCT07204275RecruitingPhase 2/Phase 3
Testing povetacicept for primary membranous nephropathy
This study tests an investigational drug called povetacicept for people with primary membranous nephropathy, a kidney disease. Researchers want to see if it is safe and helps reduce protein in the urine.
Montgomery, AlabamaAges 18–75 - NCT06781944RecruitingPhase 3
Obinutuzumab vs standard treatment for membranous nephropathy
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07163611RecruitingPhase 2/Phase 3
Obinutuzumab for PLA2R antibodies in membranous nephropathy
This study is testing a drug called obinutuzumab to see if it can lower PLA2R antibodies in people with membranous nephropathy (a kidney disease). The goal is to reduce protein leakage in urine and improve kidney health.
NijmegenAges 18 years+ - NCT06760845Recruiting
Using light to diagnose kidney disease
This trial uses a special light technique (Raman spectroscopy) to help diagnose different types of kidney disease. It may provide a faster, less invasive way to understand your condition.
Jinan, ShandongAges Any age - NCT04456816RecruitingPhase 2
Drug test for IgA? No—anti-PLA2R positive immune kidney disease
This Phase 2 trial studies AP1189 in people with a specific immune-related kidney disease called iMN and very high urine protein. It aims to see whether the drug is safe and tolerable and if it can reduce protein in the urine.
AarhusAges 18–85 - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Membranous Nephropathy trials by city
Studies with a site in or near these metro areas.
Membranous Nephropathy trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for membranous nephropathy?
- Yes. Clin2 currently lists 37 recruiting membranous nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a membranous nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a membranous nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.